Apolipoproteins C-I and C-III as important modulators of lipoprotein metabolism

Current Opinion in Lipidology

Volumn 12, Issue 3, 2001, Pages 297-304

  Shachter, Neil S ^a  

^a Och Spine at New York Presbyterian Hospitals   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

APOLIPOPROTEIN C1; APOLIPOPROTEIN C3; CHOLESTEROL ESTER TRANSFER PROTEIN; FATTY ACID; GLYCOSAMINOGLYCAN; HIGH DENSITY LIPOPROTEIN; LIPOPROTEIN LIPASE; LIPOPROTEIN RECEPTOR; LOW DENSITY LIPOPROTEIN RECEPTOR RELATED PROTEIN; TRIACYLGLYCEROL; VERY LOW DENSITY LIPOPROTEIN RECEPTOR;

ENZYME INHIBITION; FATTY ACID TRANSPORT; HUMAN; HYPERTRIGLYCERIDEMIA; LIPOLYSIS; LIPOPROTEIN METABOLISM; NONHUMAN; PRIORITY JOURNAL; PROTEIN BINDING; PROTEIN EXPRESSION; RECEPTOR BINDING; REVIEW;

ALLELES; ANIMALS; APOLIPOPROTEIN C-I; APOLIPOPROTEIN C-III; APOLIPOPROTEINS C; GENE EXPRESSION REGULATION; HUMANS; HYPERTRIGLYCERIDEMIA; LDL-RECEPTOR RELATED PROTEIN 1; LIPOPROTEINS; MICE; RECEPTORS, IMMUNOLOGIC; RECEPTORS, LDL; VARIATION (GENETICS);

EID: 0034983440     PISSN: 09579672     EISSN: None     Source Type: Journal    
DOI: 10.1097/00041433-200106000-00009     Document Type: Review

References (99)

1. Studies of the proteins in human plasma very low density lipoproteins
2. Further characterization of the apolipoproteins from the human plasma very low density lipoproteins
3. Role of ApoCs in lipoprotein metabolism: Functional differences between apoC1, apoC2, and apoC3
4. Inhibition of lipoprotein lipase by an apoprotein of human very low density lipoprotein
5. Cofactor activity of protein components of human very low density lipoproteins in the hydrolysis of triglycerides by lipoprotein lipase from different sources
6. Influence of apolipoprotein E on soluble and heparin-immobilized hepatic lipase
7. Changing relative proportions of apolipoprotein C-II and C-III of very low density lipoproteins in hypertriglyceridemia
8. Independent regulation of plasma lipoprotein C-II and C-III concentrations in very low density and high density lipoproteins: Implications for the regulation of the catabolism of these lipoproteins
9. Modulation of lipoprotein lipase activity by apolipoproteins. Effect of apolipoprotein C-III
10. Apolipoprotein B metabolism in subjects with deficiency of apolipoproteins CIII and AI
11. An apolipoprotein CIII haplotype protective against hypertriglyceridemia is specified by promoter and 3′ untranslated region polymorphisms
12. Hypertriglyceridemia as a result of human apo CIII gene expression in transgenic mice
13. Mechanism of hypertriglyceridemia in human apo CIII transgenic mice: Diminished VLDL fractional catabolic rate associated with increased apo CIII and reduced apo E on the particles
14. Overexpression of human apolipoprotein C-III in transgenic mice results in an accumulation of apolipoprotein B48 remnants that is corrected by excess apolipoprotein E
15. Targeted disruption of the apolipoprotein C-III gene in mice results in hypotriglyceridemia and protection from postprandial hypertriglyceridemia
16. Regulation of the hepatic uptake of triglyceride-rich lipoproteins in the rat. Opposing effects of homologous apolipoprotein E and individual C apolipoproteins
17. The effect of human C apolipoproteins on the in vitro hepatic metabolism of triglyceride emulsions in the rat
18. Opposing effects of apolipoprotein E and C on lipoprotein binding to low density lipoprotein receptor-related protein
19. Apolipoprotein C-I modulates the interaction of apolipoprotein E with β-migrating very low density lipoproteins (β-VLDL) and inhibits binding of β-VLDL to low density lipoprotein receptor-related protein
20. The estradiol-stimulated lipoprotein receptor of rat liver. A binding site that membrane mediates the uptake of rat lipoproteins containing apoproteins B and E
21. Mechanisms of inhibition by apolipoprotein C of apolipoprotein E-dependent cellular metabolism of human triglyceride-rich lipoproteins through the low density lipoprotein receptor pathway
22. Modulation of lipoprotein B binding to the LDL receptor by exogenous lipids and apolipoproteins CI, CII, CIII, and E
23. Reversal of hyperlipidaemia in apolipoprotein C1 transgenic mice by adenovirus-mediated gene delivery of the low-density-lipoprotein receptor, but not by the very-low-density-lipoprotein receptor
24. Effect of human plasma apolipoproteins on the activity of purified lecithin: Cholesterol acyltransferase
25. Transfer of cholesteryl ester into high density lipoprotein by cholesteryl ester transfer protein: Effect of HDL lipid and apolipoprotein content
26. Metabolic and clinical significance of plasma lipoprotein families defined by apolipoprotein composition
27. Apolipoprotein C-III, hypertriglyceridemia and triglyceride-rich lipoproteins in uremia
28. Identification of apoB-containing lipoprotein families in NIDDM
29. Triglycerides, apo C3 and Lp B:C3 and cardiovascular risk in type II diabetes
30. Effects of lovastatin on apoA-I and apoB-containing lipoproteins. Families in a subpopulation of patients participating in the Monitored Atherosclerosis Regression Study (MARS)
31. Apolipoproteins C3 and E in apoB- and non apo B-containing lipoproteins in two populations at contrasting risk for myocardial infarction: The ECTIM study
32. The effect of aggressive and moderate lowering of LDL-cholesterol and low-dose anticoagulation on plasma lipids, apolipoproteins and lipoprotein families in post coronary artery bypass graft trial
33. VLDL, apolipoproteins B, CIII, and E, and risk of recurrent coronary events in the Cholesterol and Recurrent Events (CARE) trial
34. Postprandial response to a fat tolerance test in young adults with a paternal history of premature coronary heart disease-the EARS II study
35. Alterations in plasma lipoproteins and apolipoproteins before the age of 40 in heterozygotes for lipoprotein lipase deficiency
36. Plasma kinetics of apoC-III and apoE in normolipidemic and hypertriglyceridemic subjects
37. Apolipoprotein C-III gene variation and dyslipidaemia
38. Common genetic variation in the promoter of the human apo CIII gene abolishes regulation by insulin and may contribute to hypertriglyceridemia
39. Polymorphic markers in apolipoprotein C-III gene flanking regions and hypertriglyceridemia
40. Association of plasma lipids and apolipoproteins with the insulin response element in the apoC-III promoter region in familial combined hyperlipidemia
41. Gender related association between genetic variations of APOC-III gene and lipid and lipoprotein variables in northern France
42. Plasma levels of remnant particles are determined in part by variation in the APOC3 gene insulin response element and the APOCI-APOE cluster
43. ApoCIII gene variants modulate postprandial response to both glucose and fat tolerance tests
44. Allele-specific differences in apolipoproteins C-III mRNA expression in human liver
45. Lack of association between genetic variations of apo A-I-C-III-A-IV gene cluster and myocardial infarction in a sample of European male; ECTIM study
46. Complex genetic contribution of the Apo AI-CIII-AIV gene cluster to familial combined hyperlipidemia. Identification of different susceptibility haplotypes
47. Severe hyperlipidemia in apolipoproteins E2 homozygotes due to a combined effect of hyperinsulinemia and an Sstl polymorphism
48. Contribution of apolipoproteins C-III gene variants to determination of triglyceride levels and interaction with smoking in middle-aged men
49. Mode of action of peroxisome proliferators as hypolipidemic drugs. Suppression of apolipoprotein C-III
50. Cell culture conditions determine apolipoproteins CIII secretion and regulation by fibrates in human hepatoma HepG2 cells
51. Postprandial concentrations and distribution of apo C-III in type 2 diabetic patients. Effect of bezafibrate treatment
52. Delayed catabolism of apoB-48 lipoproteins due to decreased heparan sulfate proteoglycan production in diabetic mice
53. Retinoids increase human apo C-III expression at the transcriptional level via the retinoid X receptor. Contribution to the hypertriglyceridemic action of retinoids
54. Percxisome proliferator-activated receptor alpha-mediated pathways are altered in hepatocyte-specific retinoid X receptor alpha-deficient mice
55. 3-Hydroxy-3-methylglutaryl CoA reductase inhibitors reduce serum triglyceride levels through modulation of apolipoproteins C-III and lipoprotein lipase
56. Mitogen-activated protein kinase regulates transcription of the apoCIII gene
57. Mutations in the HNF-4alpha gene affect insulin secretion and triglyceride metabolism
58. Genotype/phenotype relationships in HNF-4alpha/MODY1: Haploinsufficiency is associated with reduced apolipoprotein (AII), apolipoprotein (CIII), lipoprotein(a), and triglyceride levels
59. Familial apolipoprotein Al and apolipoprotein CIII deficiency. Subclass distribution, composition, and morphology of lipoproteins in a disorder associated with premature atherosclerosis
60. Hydrolysis of phospholipids by purified milk lipoprotein lipase. Effect of apoprotein CII, CIII, A and E, and synthetic fragments
61. Characterization of recombinant wild type and site-directed mutations of apolipoproteins C-III: Lipid binding, displacement of ApoE, and inhibition of lipoprotein lipase
62. Characterization of the lipid-binding properties and lipoprotein lipase inhibition of a novel apolipoprotein C-III variant Ala23Thr
63. High density lipoprotein metabolism
64. Abnormal activation of lipoprotein lipase by non-equilibrating pools of apolipoproteins C-II and C-III in plasma lipoproteins
65. Kinetics and mechanism of exchange of apolipoproteins C-III molecules from very low density lipoprotein particles
66. Apolipoprotein C-III displacement of apolipoprotein E from VLDL: Effect of particle size
67. Spontaneous hypercholesterolemia and arterial lesions in mice lacking apolipoprotein E
68. Severe hypercholesterolemia and atherosclerosis in apolipoprotein E-deficient mice created by homologous recombination in ES cells
69. Targeted disruption of the apolipoprotein C-III gene in mice results in hypertriglyceridemia and protection from postprandial hypertriglyceridemia
70. Overexpression of apolipoprotein CII causes hypertriglyceridemia in transgenic mice
71. Combined hyperlipidemia in transgenic mice overexpressing human apolipoprotein CI
72. Chylomicronemia due to apolipoprotein CIII overexpression in apolipoprotein E-null mice. Apolipoprotein CIII-induced hypertriglyceridemia is not mediated by effects on apolipoprotein E
73. Level of apoC-III mRNA correlates positively to the secretion of triglyceride-rich VLDL from transfected McA-RH7777 cells
74. Expression of human apolipoproteins A-I/C-III/A-IV gene cluster in mice induces hyperlipidemia but reduces atherogenesis
75. Decreased early atherosclerotic lesions in hypertriglyceridemic mice expressing cholesteryl ester transfer protein transgene
76. A mouse model with features of familial combined hyperlipidemia
77. Massive xanthomatosis and atherosclerosis in cholesterol-fed low density lipoprotein receptor-negative mice
78. Plasma lipoproteins and progression of coronary artery disease evaluated by angiography and clinical events
79. Postprandial lipoprotein metabolism in normolipidemic men with and without coronary artery disease
80. Association of postprandial triglyceride and retinyl palmitate responses with newly diagnosed exercise-induced myocardial ischemia in middle-aged men and women
81. Association of postprandial triglyceride and retinyl palmitate responses with asymptomatic carotid artery atherosclerosis in middle-aged men and women. The Atherosclerosis Risk in Communities (ARIC) Study
82. Accumulation of apolipoprotein C-I-rich and cholesterol-rich VLDL remnants during exaggerated postprandial triglyceridemia in normolipidemic patients with coronary artery disease
83. Alterations of VLDL composition during alimentary lipemia
84. Differences in apolipoprotein and lipid composition between human chylomicron remnants and very low density lipoproteins isolated from fasting and postprandial plasma
85. Human apolipoprotein C-I accounts for the ability of plasma high density lipoproteins to inhibit the cholesteryl ester transfer protein activity
86. A common Hpa I RFLP of apolipoprotein C-I increases gene transcription and exhibits an ethnically distinct pattern of linkage disequilibrium with the alleles of apolipoprotein E
87. Haplotype analysis of the apolipoprotein E and apolipoprotein C1 loci in Portugal and Sao Tome e Principe (Gulf of Guinea): Linkage disequilibrium evidence that APOE*4 is the ancestral APOE allele
88. Interaction of the apolipoprotein E and CI loci in predisposing to late-onset Alzheimer's disease
89. Long terminal repeats are used as alternative promoters for the endothelin B receptor and apolipoprotein C-I genes in humans
90. Developmental and pharmacological regulation of apolipoprotein C-II gene expression. Comparison with apo C-I and apo C-III gene regulation
91. Multiple tissue-specific elements control the apolipoprotein E/C-I gene locus in transgenic mice
92. Two hepatic enhancers, HCR.1 and HCR.2, coordinate the liver expression of the entire human apolipoprotein E/C-I/C-IV/C-II gene cluster
93. Duplicated downstream enhancers control expression of the human apolipoprotein E gene in macrophages and adipose tissue
94. Increased response to cholesterol feeding in apolipoprotein C1-deficient mice
95. Localization of a liver-specific enhancer in the apolipoprotein E/CI/CII gene locus
96. Both lipolysis and hepatic uptake of VLDL are impaired in transgenic mice coexpressing human apolipoprotein E*3Leiden and human apolipoprotein C-I
97. In the absence of the low density lipoprotein receptor, human apolipoprotein C-I overexpression in transgenic mice inhibits the hepatic uptake of very low density lipoproteins via a receptor-associated protein-sensitive pathway
98. Hyperlipidemia and cutaneous abnormalities in transgenic mice overexpressing human apolipoprotein C1
99. Hyperlipidemia is associated with increased insulin mediated glucose metabolism, reduced fatty acid metabolism and normal blood pressure in transgenic mice overexpressing human apolipoproteins C1